Full program (PDF)
Plenary Session 1 Genome Expression and Maintenance
DNA within chromatin regulates gene expression, influences cellular responses and is at the heart of cancer genetics and epigenetics. It is essential to understand how DNA and epigenetic alterations contribute to signaling pathways and impact treatment strategies. It also enables genomics to be exploited for precision medicine and biomarker discovery, making it an essential component of global cancer research.
John Diffley
The Francis Crick Institute, London, UK
Mathieu Lupien
Princess Margaret Cancer Centre, University of Toronto
Nada Jabado
Research Institute of the McGill University Health Centre, Montreal
Jacques Côté
Centre de recherche du CHU de Québec-Université Laval
Plenary Session 2 Regulation by Coding and Non-Coding RNAs
RNA molecules, both coding and non-coding, play an essential role in modulating gene expression and influencing cell signaling pathways. Understanding the complex mechanisms by which RNA participates in cancer-related signaling events is essential to unravel the complexities of the disease. This session will explore emerging areas such as the impact of non-coding RNA on oncogenic pathways, potentially revealing new therapeutic targets and diagnostic markers. In addition, RNA-based technologies and therapies, such as mRNA vaccines, are gaining importance in cancer treatment, making it imperative to keep abreast of these advances as part of the symposium.
Nahum Sonenberg
Goodman Cancer Institute, McGill University, Montreal
Katherine Borden
Institut de Recherche en Immunologie et Cancérologie, Université de Montréal
Ly Vu
Terry Fox Laboratory, British Columbia Cancer Research Centre, Vancouver
Martin Simard
Centre de recherche du CHU de Québec-Université Laval
Plenary Session 3 Protein Dynamics and Cell Communications
Understanding the role of proteins and cellular communications in oncogenic pathways is fundamental to identifying therapeutic targets and biomarkers. In addition, targeted therapies often focus on the inhibition or modulation of specific proteins, making this session an integral part of advancing cancer treatment strategies.
Christian Landry
Institut de Biologie Intégrative et des Systèmes, Université Laval
Anne-Claude Gingras
Lunenfeld-Tanenbaum Research Institute, University of Toronto
Marc Therrien
Institut de Recherche en Immunologie et Cancérologie, Université de Montréal
Nicolas Bisson
Centre de recherche du CHU de Québec-Université Laval
Elaine Fuchs
Howard Hughes Medical Institute, The Rockefeller University, New York
Panels:
-The Future in Cell Signaling Research
-Diversity of careers in cancer research (this part will be in French)
10 conférences éclair suivies d'un panel de discussion
Panel #1 : Carrières au public et parapublic
Panel #2 : Carrières au privé et entreprenariat